Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 3Graft vs Host Disease 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Myeloproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hodgkin Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 21fludarabine 20fludarabine phosphate 17Tacrolimus 12thymoglobulin 11Whole-Body Irradiation 11Busulfan 10Azacitidine 10Mycophenolic Acid 9Methotrexate 9Thiotepa 8Melphalan 8Antilymphocyte Serum 8venetoclax 7AP 1903 reagent 7Rituximab 6Sirolimus 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Cytarabine 5Cord Blood Stem Cell Transplantation 5merphos 4aldesleukin 4Peripheral Blood Stem Cell Transplantation 4Nivolumab 4Interleukin-2 4Dexamethasone 4enasidenib 3Tretinoin 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Calcineurin Inhibitors × Myeloid × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT01379209 2019-10-23

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Regimmune Corporation

Phase 1/2 Completed
68 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡